Recherche
-
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
(NPJ vaccines. vol. 8, n° 1, pp. 174, 2023-11-08)Article de revueLibre accès -
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
(eLife. vol. 11, pp. e75427, 2022-07-08)Article de revueLibre accès -
Barrier Gesture Relaxation during Vaccination Campaign in France: Modelling Impact of Waning Immunity
(COVID. vol. 1, n° 2, pp. 472-488, 2021-10-09)Article de revueLibre accès -
Impact of non-pharmaceutical interventions, weather, vaccination, and variants on COVID-19 transmission across departments in France: a modelling study
Document de travail - Pré-publicationLibre accès -
Evaluating the Use of Generalized Dynamic Weighted Ordinary Least Squares for Individualized Hiv Treatment Strategies
(Annals of Applied Statistics. vol. 17, n° 3, pp. 2432-2451, 2023-09)Article de revueLibre accès -
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
(PLoS Medicine. vol. 19, n° 1, 2022-01-11)Article de revueLibre accès -
Global Variations in Event-Based Surveillance for Disease Outbreak Detection: Time Series Analysis
(JMIR Public Health and Surveillance. vol. 8, n° 10, 2022-10-31)Article de revueLibre accès -
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)
(Trials. vol. 21, n° 1, pp. 846, 2020-10-13)Article de revueLibre accès -
Post-clustering difference testing: valid inference and practical considerations
(Computational Statistics and Data Analysis)Article de revueLibre accès -
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE).
(Clinical Microbiology and Infection. vol. 28, n° 7, pp. 1010-1016, 2022-07-01)Article de revueLibre accès